10x Genomics (TXG) Revenue (2018 - 2026)

10x Genomics has disclosed Revenue across 9 years of filings, most recently posting $150.8 million for Q1 2026.

• Revenue for Q1 2026 came in at $150.8 million, down 2.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $638.8 million (up 2.26% YoY), and the FY2025 annual result was $642.8 million, up 5.25% from the prior year.
• Revenue came in at $150.8 million for Q1 2026 at 10x Genomics, down from $166.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $184.0 million in Q4 2023 to a low of $114.5 million in Q1 2022.
• The 5-year median for Revenue is $151.7 million (2024), against an average of $149.4 million.
• Across the five-year window, Revenue rose 28.1% in 2023 and decreased 10.3% in 2024, its largest moves.
• 10x Genomics' Revenue stood at $156.2 million in 2022, then rose by 17.76% to $184.0 million in 2023, then fell by 10.3% to $165.0 million in 2024, then increased by 0.61% to $166.0 million in 2025, then declined by 9.15% to $150.8 million in 2026.
• The last three Revenue figures came in at $150.8 million (Q1 2026), $166.0 million (Q4 2025), and $149.0 million (Q3 2025), per Business Quant data.